These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23630972)

  • 1. [Idiopathic pulmonary fibrosis: treatment with pirfenidone].
    Cano-Jiménez E
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():16-8. PubMed ID: 23630972
    [No Abstract]   [Full Text] [Related]  

  • 2. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 3. POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes.
    King CS; Nathan SD
    Chest; 2016 Aug; 150(2):273-5. PubMed ID: 27292047
    [No Abstract]   [Full Text] [Related]  

  • 4. [Patient treated with pirfenidone].
    Valenzuela C
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():19-20. PubMed ID: 23630973
    [No Abstract]   [Full Text] [Related]  

  • 5. COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.
    Brown KK
    Chest; 2016 Aug; 150(2):276-8. PubMed ID: 27292046
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe Colitis Associated with Pirfenidone Use in Idiopathic Pulmonary Fibrosis.
    Fiddler CA; Simler N; Parfrey H; Miremadi A; Chilvers ER
    Ann Am Thorac Soc; 2016 Aug; 13(8):1430-2. PubMed ID: 27509160
    [No Abstract]   [Full Text] [Related]  

  • 7. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 8. Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.
    Selvaggio AS; Noble PW
    Annu Rev Med; 2016; 67():487-95. PubMed ID: 26565677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.
    Raghu G; Selman M
    Am J Respir Crit Care Med; 2015 Feb; 191(3):252-4. PubMed ID: 25635489
    [No Abstract]   [Full Text] [Related]  

  • 10. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Poletti V; Ravaglia C; Tomassetti S
    Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone treatment of idiopathic pulmonary fibrosis.
    Azuma A
    Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].
    Tokura T; Oku H; Tsukamoto Y
    Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):97-104. PubMed ID: 19672005
    [No Abstract]   [Full Text] [Related]  

  • 13. Is pirfenidone effective for idiopathic pulmonary fibrosis?
    Jeldres A; Labarca G
    Medwave; 2017 Jan; 17(Suppl1):e6843. PubMed ID: 28112713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis.
    Bando M
    Respir Investig; 2016 Sep; 54(5):298-304. PubMed ID: 27566376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
    Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
    Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
    [No Abstract]   [Full Text] [Related]  

  • 16. Pirfenidone for idiopathic pulmonary fibrosis.
    Bouros D
    Lancet; 2011 May; 377(9779):1727-9. PubMed ID: 21571363
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
    Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
    Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone.
    Varone F; Mastrobattista A; Franchi P; Viglietta L; Poletti V; Tomassetti S; Dubini A; Tagliaboschi L; Calandriello L; Farchione A; Larici AR
    Clin Respir J; 2018 Jan; 12(1):347-351. PubMed ID: 27322356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
    Glassberg MK; Wijsenbeek MS; Gilberg F; Petzinger U; Kirchgaessler KU; Albera C
    Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31164431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.